Use of Magnetization Transfer Contrast MRI to Detect Early Molecular Pathology in Alzheimer's Disease
Article first published online: 14 FEB 2013
Copyright © 2013 Wiley Periodicals, Inc.
Magnetic Resonance in Medicine
Volume 71, Issue 1, pages 333–338, January 2014
How to Cite
Pérez-Torres, C. J., Reynolds, J. O. and Pautler, R. G. (2014), Use of Magnetization Transfer Contrast MRI to Detect Early Molecular Pathology in Alzheimer's Disease. Magn Reson Med, 71: 333–338. doi: 10.1002/mrm.24665
- Issue published online: 17 DEC 2013
- Article first published online: 14 FEB 2013
- Manuscript Accepted: 9 JAN 2013
- Manuscript Received: 16 NOV 2012
- NIH. Grant Number: R01AG029977
- Mitchell Foundation, Anonymous Foundation
- magnetization transfer;
- amyloid beta;
- Alzheimer's disease
The purpose of this study was to determine if magnetization transfer contrast (MTC) imaging could be used to detect early macromolecular accumulation in a mouse model of early Alzheimer's disease.
We obtained MTC images at 9.4 T at three different age points in the Tg2576 mouse model of Alzheimer's disease. The Tg2576 mouse exhibits increased amyloid beta deposition that eventually progresses into amyloid beta plaque formation, increased hyper-phosphorylated tau but does not exhibit neurodegeneration.
Our results show an increase in the MTC signal that predates plaque formation and reported learning and memory deficits in the Tg2576 mouse. This increase in the MTC signal was reversed in a model of antioxidant therapy.
MTC magnetic resonance imaging can be used to detect early macromolecular changes in the Tg2576 mouse model of Alzheimer's disease. The source of the MTC contrast is likely complex and warrants further investigation in additional preclinical models that represent early and late stage Alzheimer's disease pathologies. Magn Reson Med 71:333–338, 2014. © 2013 Wiley Periodicals, Inc.